View Future GrowthMesa Laboratories 過去の業績過去 基準チェック /36Mesa Laboratoriesの収益は年間平均-37.2%の割合で減少していますが、 Life Sciences業界の収益は年間 増加しています。収益は年間4.4% 10%割合で 増加しています。 Mesa Laboratoriesの自己資本利益率は3.6%であり、純利益率は2.7%です。主要情報-37.16%収益成長率-37.21%EPS成長率Life Sciences 業界の成長26.83%収益成長率10.01%株主資本利益率3.60%ネット・マージン2.69%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • May 27Full year 2026 earnings released: EPS: US$1.22 (vs US$0.36 loss in FY 2025)Full year 2026 results: EPS: US$1.22 (up from US$0.36 loss in FY 2025). Revenue: US$249.1m (up 3.4% from FY 2025). Net income: US$6.71m (up US$8.69m from FY 2025). Profit margin: 2.7% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • May 06Mesa Laboratories, Inc. to Report Q4, 2026 Results on May 27, 2026Mesa Laboratories, Inc. announced that they will report Q4, 2026 results at 6:00 AM, US Eastern Standard Time on May 27, 2026お知らせ • Oct 03+ 1 more updateMesa Laboratories, Inc. to Report Q2, 2026 Results on Nov 06, 2025Mesa Laboratories, Inc. announced that they will report Q2, 2026 results After-Market on Nov 06, 2025お知らせ • Jul 03Mesa Laboratories, Inc. to Report Q1, 2026 Results on Aug 05, 2025Mesa Laboratories, Inc. announced that they will report Q1, 2026 results at 8:00 AM, US Eastern Standard Time on Aug 05, 2025お知らせ • Jan 19Mesa Laboratories, Inc. to Report Q3, 2025 Results on Feb 04, 2025Mesa Laboratories, Inc. announced that they will report Q3, 2025 results at 8:00 AM, Eastern Standard Time on Feb 04, 2025Reported Earnings • Nov 08Second quarter 2025 earnings released: EPS: US$0.63 (vs US$0.23 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.63 (up from US$0.23 loss in 2Q 2024). Revenue: US$57.8m (up 8.8% from 2Q 2024). Net income: US$3.43m (up US$4.66m from 2Q 2024). Profit margin: 5.9% (up from net loss in 2Q 2024). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.すべての更新を表示Recent updatesRecent Insider Transactions • Jun 29Insider recently sold €197k worth of stockOn the 22nd of June, Brian Archbold sold around 3k shares on-market at roughly €78.21 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €197k more than they bought in the last 12 months.お知らせ • Jun 16Mesa Laboratories, Inc. Announces Appointment of Lyndsey Crennen as Chief Accounting OfficerMesa Laboratories, Inc. approved the appointment of Lyndsey Crennen as the Chief Accounting Officer of the Company, effective as of her entry into the Employment Agreement. Lyndsey Crennen, age 41, has over 20 years of experience in accounting and related roles. Lyndsey Crennen joined Mesa in 2018 as Assistant Controller and has held progressive accounting roles at the Company, including serving as Corporate Controller since 2022. Prior to joining Mesa, Lyndsey Crennen worked at Chipotle Mexican Grill, Inc., where she led the internal audit function from 2012 to 2014 and subsequently oversaw technical accounting and financial reporting through 2018. Lyndsey Crennen began her career as an auditor at PricewaterhouseCoopers, LLP in Denver. Lyndsey Crennen holds a B.S. degree in accounting and finance from the University of Colorado and is a Certified Public Accountant.New Risk • Jun 04New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.7x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.7x net interest cover). Minor Risk Share price has been volatile over the past 3 months (9.5% average weekly change).New Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • May 27Full year 2026 earnings released: EPS: US$1.22 (vs US$0.36 loss in FY 2025)Full year 2026 results: EPS: US$1.22 (up from US$0.36 loss in FY 2025). Revenue: US$249.1m (up 3.4% from FY 2025). Net income: US$6.71m (up US$8.69m from FY 2025). Profit margin: 2.7% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Declared Dividend • May 20Third quarter dividend of US$0.16 announcedShareholders will receive a dividend of US$0.16. Ex-date: 29th May 2026 Payment date: 15th June 2026 Dividend yield will be 0.7%, which is higher than the industry average of 0.5%. Payout Ratios Payout ratio: 94%. Cash payout ratio: 9%.お知らせ • May 06Mesa Laboratories, Inc. to Report Q4, 2026 Results on May 27, 2026Mesa Laboratories, Inc. announced that they will report Q4, 2026 results at 6:00 AM, US Eastern Standard Time on May 27, 2026お知らせ • Apr 03Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2026Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026.お知らせ • Mar 10+ 1 more updateMesa Laboratories, Inc. Announces Management Changes, Effective on or About April 13, 2026On March 3, 2026, Mesa Laboratories, Inc. initiated a leadership transition pursuant to which Gary Owens will depart as President of the Company, effective on or about April 13, 2026 (the “Transition Date”). In connection with Mr. Owens’ departure, the Board has appointed Dr. Siddhartha Kadia to serve as the Company’s new President and Chief Executive Officer, effective on or about April 13, 2026 (the “Effective Date”). The Board has also approved the appointment of Dr. Kadia as a member of the Board, effective as of the Effective Date. Dr. Kadia, age 56, is an experienced executive with over 20 years in the life sciences, diagnostics and biotechnology sectors. Since January 2025, Dr. Kadia has served as Chief Executive Officer of Calibre Scientific, a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. From March 2022 to August 2023, he served as Chief Executive Officer of PhenomeX and its predecessor Berkeley Lights until its acquisition by Bruker Corporation. From 2014 to 2018, he served as Chief Executive Officer of EAG Laboratories. From 2005 to 2014, he served in various roles at Life Technologies (formerly Invitrogen Corporation), including President of the company’s Life Sciences Division, until the company was acquired by Thermo Fisher Scientific. Dr. Kadia began his career at consultancy firm McKinsey & Company, where he worked from 2001 to 2005. Dr. Kadia holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine, where he was honored with the David Israel Macht Award for Excellence in Research, and a Masters of Science in Biomedical Engineering from Rutgers University.お知らせ • Feb 18Mesa Laboratories, Inc. Announces Renewed Commitment to Advancing Primary Standard Calibration Technology Through its DryCal Product LineMesa Laboratories, Inc. announced a renewed commitment to advancing primary standard calibration technology through its DryCal product line, as occupational health and safety professionals confront rising regulatory scrutiny and a generational workforce transition that threatens the integrity of workplace exposure monitoring. Across industries from pharmaceutical manufacturing to construction, worker safety depends on the accuracy of air sampling pumps used to measure exposure to hazardous substances. Those pumps must be calibrated to strict standards set by the Occupational Safety and Health Administration (OSHA) and the National Institute for Occupational Safety and Health (NIOSH), which require calibrator accuracy of +-1%. Yet a growing share of the calibration market relies on secondary standard instruments that can degrade to +-4-20% error at low flow rates, the very conditions most critical to detecting harmful exposures. Mesa's DryCal technology uses a proprietary piston prover, a primary standard that measures gas flow directly from fundamental SI quantities of volume and time. Unlike secondary standards, which derive flow measurements directly from pressure drop, temperature, and gas viscosity assumptions, a primary standard maintains accuracy across its full operating range without depending on environmental conditions or gas-specific properties. If contamination enters the measurement cell, the DryCal's piston stops moving before it can produce an inaccurate reading, a fail-safe design that secondary instruments, which can drift silently when compromised, do not offer. The distinction between primary and secondary standards has taken on new urgency as OSHA has chosen to standardize its own field enforcement operations on Mesa's Defender series calibrators, purchasing more than 120 units in 2025 with additional orders planned for 2026. As part of its commitment to advancing calibration education across the profession, Mesa Labs is partnering with the American Industrial Hygiene Association (AIHA) to present a webinar, "Flow Calibration Essentials for the OHS Professional," featuring Parameshwar alongside Laurence R. Durio, M.S., CIH, a certified industrial hygienist with more than 50 years of experience, including prior service with OSHA enforcement. The session addresses the science behind primary standards, regulatory requirements, and best practices for avoiding sample inspections. A recording is available through the AIHA website. Mesa's Calibration Solutions division continues to invest in education, product innovation, and expanded service capabilities to support occupational health and safety professionals worldwide. The company's mission, Protecting the V vulnerable®?, is reflected in its commitment to ensuring that the instruments behind workplace exposure decisions meet the highest standards of accuracy and defensibility.お知らせ • Jan 08Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 16, 2026Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026.お知らせ • Nov 07Mesa Laboratories, Inc. Provides Revenue Guidance for the Third Quarter 2026Mesa Laboratories, Inc. provided revenue guidance for the third quarter 2026. For the quarter, the company expect revenues to sequentially increase.お知らせ • Oct 03+ 1 more updateMesa Laboratories, Inc. to Report Q2, 2026 Results on Nov 06, 2025Mesa Laboratories, Inc. announced that they will report Q2, 2026 results After-Market on Nov 06, 2025お知らせ • Jul 14Mesa Laboratories, Inc., Annual General Meeting, Aug 22, 2025Mesa Laboratories, Inc., Annual General Meeting, Aug 22, 2025. Location: mesa laboratories, lakewood, colorado 80228, United Statesお知らせ • Jul 04Mesa Labs Declares Quarterly Dividend, Payable on September 15, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025.お知らせ • Jul 03Mesa Laboratories, Inc. to Report Q1, 2026 Results on Aug 05, 2025Mesa Laboratories, Inc. announced that they will report Q1, 2026 results at 8:00 AM, US Eastern Standard Time on Aug 05, 2025お知らせ • Jun 30+ 7 more updatesMesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell 2000 Value IndexMesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell 2000 Value Indexお知らせ • Apr 08Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 16, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025.お知らせ • Jan 19Mesa Laboratories, Inc. to Report Q3, 2025 Results on Feb 04, 2025Mesa Laboratories, Inc. announced that they will report Q3, 2025 results at 8:00 AM, Eastern Standard Time on Feb 04, 2025お知らせ • Jan 07Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 17, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025.Reported Earnings • Nov 08Second quarter 2025 earnings released: EPS: US$0.63 (vs US$0.23 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.63 (up from US$0.23 loss in 2Q 2024). Revenue: US$57.8m (up 8.8% from 2Q 2024). Net income: US$3.43m (up US$4.66m from 2Q 2024). Profit margin: 5.9% (up from net loss in 2Q 2024). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.Recent Insider Transactions • Nov 01CEO, President & Director recently sold €529k worth of stockOn the 29th of October, Gary Owens sold around 5k shares on-market at roughly €104 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Gary's only on-market trade for the last 12 months.Declared Dividend • Oct 06First quarter dividend of US$0.16 announcedShareholders will receive a dividend of US$0.16. Ex-date: 29th November 2024 Payment date: 16th December 2024 Dividend yield will be 0.5%, which is about the same as the industry average.お知らせ • Oct 03Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 16, 2024Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.Declared Dividend • Jul 29Fourth quarter dividend of US$0.16 announcedShareholders will receive a dividend of US$0.16. Ex-date: 30th August 2024 Payment date: 16th September 2024 Dividend yield will be 0.6%, which is about the same as the industry average.お知らせ • Jul 22Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024. Location: corporate headquarters at 12100 west sixth avenue, lakewood, colorado 80228., United Statesお知らせ • Jul 09Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024Mesa Laboratories, Inc. announced that its Board of Directors have declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024.お知らせ • Jun 16Mesa Laboratories, Inc. announced delayed annual 10-K filingOn 06/14/2024, Mesa Laboratories, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.Reported Earnings • Jun 06Full year 2024 earnings released: US$47.21 loss per share (vs US$0.17 profit in FY 2023)Full year 2024 results: US$47.21 loss per share (down from US$0.17 profit in FY 2023). Revenue: US$216.2m (down 1.3% from FY 2023). Net loss: US$254.2m (down US$255.2m from profit in FY 2023). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 133 percentage points per year, which is a significant difference in performance.お知らせ • Jun 06Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024Mesa Laboratories, Inc. reported Impairment of goodwill and long-lived assets for the fourth quarter ended March 31, 2024 of $274,533,000.New Risk • May 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.3x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Large one-off items impacting financial results.Upcoming Dividend • May 24Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 31 May 2024. Payment date: 14 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.6%). In line with average of industry peers (0.6%).Declared Dividend • Apr 15Third quarter dividend of US$0.16 announcedShareholders will receive a dividend of US$0.16. Ex-date: 31st May 2024 Payment date: 14th June 2024 Dividend yield will be 0.6%, which is higher than the industry average of 0.5%. Payout Ratios Payout ratio: 363%. Cash payout ratio: 8%.お知らせ • Apr 05Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024Mesa Laboratories, Inc. announced that its board of directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024.New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.3x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results.お知らせ • Apr 02Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024Mesa Laboratories, Inc. announced that they will report Q4, 2024 results at 8:00 AM, US Eastern Standard Time on May 24, 2024Upcoming Dividend • Feb 21Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 28 February 2024. Payment date: 15 March 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (5.2%). In line with average of industry peers (0.7%).Reported Earnings • Feb 05Third quarter 2024 earnings released: EPS: US$0.39 (vs US$0.084 in 3Q 2023)Third quarter 2024 results: EPS: US$0.39 (up from US$0.084 in 3Q 2023). Revenue: US$53.5m (down 1.5% from 3Q 2023). Net income: US$2.12m (up 369% from 3Q 2023). Profit margin: 4.0% (up from 0.8% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.お知らせ • Jan 08Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of DirectorsMesa Laboratories, Inc. announced the appointment of Mark Capone to its Board of Directors, effective January 5, 2024. Following Mr. Capone’s election, the Mesa Board will be comprised of 7 directors, the majority of whom are independent. The Board is committed to ongoing director refreshment and continues to consider new, qualified independent directors. Mr. Capone most recently served as CEO and President of Myriad Genetics for five years. Prior to his appointment as CEO and President, he held various progressive leadership roles at Myriad Genetics, with a total tenure of 17 years at the company. During his leadership tenure, he oversaw Myriad Genetics’ growth from an early-stage pioneer in molecular diagnostics into a leading global precision medicine company. Prior to his tenure at Myriad Genetics, Mr. Capone spent 17 years with Eli Lilly and Company in positions across the entire value chain. In addition to his executive leadership positions, Mr. Capone is a Non-Executive Director and member of the Compensation Committee for of Owlstone Medical Ltd, a breath biopsy diagnostic company focused on early detection of cancer and precision medicine, and a Non-Executive Director and member of the Audit Committee and Financing Committee of DermTech, a U.S. based company focused on early melanoma detection and other skin applications. Previously, Mr. Capone was a director at Abcam PLC, helping to guide that company through its acquisition by Danaher Corporation. Mr. Capone holds a Bachelor of Science in Chemical Engineering from Pennsylvania State University and a M.Sc. in Management and a M.Sc.in Chemical Engineering from Massachusetts Institute of Technology.お知らせ • Jan 05Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024Mesa Laboratories, Inc. announced that on January 2, 2024 its Board of Directors declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2024, to shareholders of record at the close of business on February 29, 2024.お知らせ • Dec 15Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024Mesa Laboratories, Inc. announced that they will report Q3, 2024 results at 8:00 AM, US Eastern Standard Time on Feb 05, 2024Upcoming Dividend • Nov 22Upcoming dividend of US$0.16 per share at 0.7% yieldEligible shareholders must have bought the stock before 29 November 2023. Payment date: 15 December 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (0.9%).New Risk • Nov 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.Reported Earnings • Nov 07Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.24 profit in 2Q 2023)Second quarter 2024 results: US$0.23 loss per share (down from US$0.24 profit in 2Q 2023). Revenue: US$53.2m (down 9.5% from 2Q 2023). Net loss: US$1.23m (down 194% from profit in 2Q 2023). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.お知らせ • Oct 18Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million on October 16, 2023. The total purchase price for the acquisition of the entity along with other 2 entities is €85 million, subject to customary purchase price adjustments and holdbacks. Collectively the three entities are referred to as “GKE”. The transactions were or will be funded with proceeds from our credit facility and cash on hand. The transaction is subject to customary conditions, including receipt of applicable Chinese regulatory approvals and is expected to be completed during our third quarter ending December 31, 2023.お知らせ • Oct 17Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million on October 16, 2023. The consideration will be paid in cash and will be funded with proceeds from credit facility and cash on hand. In a related transaction Mesa Laboratories, Inc. (NasdaqGS:MLAB) will acquire Beijing GKE Science & Technology Co. LTD for €5 million. Mesa Laboratories, Inc. (NasdaqGS:MLAB) completed the acquisition of Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH on October 16, 2023.お知らせ • Oct 05Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2023, to shareholders of record at the close of business on November 30, 2023.お知らせ • Sep 14Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023Mesa Laboratories, Inc. announced that they will report Q2, 2024 results at 8:00 AM, US Eastern Standard Time on Nov 06, 2023Upcoming Dividend • Aug 23Upcoming dividend of US$0.16 per share at 0.5% yieldEligible shareholders must have bought the stock before 30 August 2023. Payment date: 15 September 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (0.8%).Reported Earnings • Aug 06First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.27 loss in 1Q 2023)First quarter 2024 results: US$0.10 loss per share (improved from US$0.27 loss in 1Q 2023). Revenue: US$50.6m (flat on 1Q 2023). Net loss: US$549.0k (loss narrowed 62% from 1Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.New Risk • Jul 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (0.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).お知らせ • Jul 15Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023, at 09:00 Mountain Standard Time. Location: corporate headquarters at 12100 West Sixth Avenue Lakewood Colorado United States Agenda: To consider election of six director nominees for a term of one year; to consider ratification of the selection by the company's Audit Committee of Plante & Moran, PLLC to serve as the company's independent registered public accounting firm for the fiscal year ending March 31, 2024; to consider an advisory vote on executive compensation; to consider approval of an Amendment to the 2021 Equity Incentive Plan; and to consider other matters.お知らせ • Jun 22Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023Mesa Laboratories, Inc. announced that they will report Q1, 2024 results at 8:00 AM, US Eastern Standard Time on Aug 03, 2023Reported Earnings • May 26Full year 2023 earnings released: EPS: US$0.17 (vs US$0.36 in FY 2022)Full year 2023 results: EPS: US$0.17 (down from US$0.36 in FY 2022). Revenue: US$219.1m (up 19% from FY 2022). Net income: US$930.0k (down 50% from FY 2022). Profit margin: 0.4% (down from 1.0% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Buying Opportunity • May 25Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €174, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company became loss making.Upcoming Dividend • May 23Upcoming dividend of US$0.16 per share at 0.4% yieldEligible shareholders must have bought the stock before 30 May 2023. Payment date: 15 June 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.7%).お知らせ • May 10Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-ElectionMesa Laboratories, Inc. announced that on May 3, 2023, John B. Schmieder, member of the Board of Directors, current Chair of the Nominating and Governance Committee, and member of the Audit Committee, informed the Board of Mesa Laboratories, Inc. that he has decided not to stand for re-election at the 2023 annual meeting of shareholders. Mr. Schmieder’s decision not to stand for re-election is not related to any disagreement with Mesa or with Mesa’s operations, policies or practices, and Mr. Schmieder will continue to serve as a director through the date of the annual meeting.Upcoming Dividend • Feb 20Upcoming dividend of US$0.16 per share at 0.4% yieldEligible shareholders must have bought the stock before 27 February 2023. Payment date: 15 March 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.7%).Reported Earnings • Feb 08Third quarter 2023 earnings released: EPS: US$0.084 (vs US$0.39 loss in 3Q 2022)Third quarter 2023 results: EPS: US$0.084 (up from US$0.39 loss in 3Q 2022). Revenue: US$54.3m (flat on 3Q 2022). Net income: US$451.0k (up US$2.51m from 3Q 2022). Profit margin: 0.8% (up from net loss in 3Q 2022). Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.お知らせ • Jan 04Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2023, to shareholders of record at the close of business on February 28, 2023.お知らせ • Dec 17Mesa Laboratories, Inc. to Report Q3, 2023 Results on Feb 06, 2023Mesa Laboratories, Inc. announced that they will report Q3, 2023 results at 8:00 AM, Eastern Standard Time on Feb 06, 2023Buying Opportunity • Dec 01Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be €199, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Meanwhile, the company became loss making.Upcoming Dividend • Nov 22Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 29 November 2022. Payment date: 15 December 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (1.5%).お知らせ • Nov 18Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH.Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH on November 17, 2022. Mesa Laboratories, Inc. (NasdaqGS:MLAB) completed the acquisition of Substantially all of the assets and certain liabilities from Belyntic GmbH on November 17, 2022.お知らせ • Nov 05+ 1 more updateMesa Laboratories, Inc. Appoints Tony Tripeny as Member of Audit CommitteeMesa Laboratories, Inc. announced on November 2, 2022, effective immediately, the Board appointed Mr. Tony Tripeny to its Audit Committee, having previously determined that he satisfies all applicable requirements to serve on the Committee, including without limitation applicable requirements of the Nasdaq Stock Market and the Securities Exchange Act of 1934, as amended.Reported Earnings • Nov 04Second quarter 2023 earnings released: EPS: US$0.24 (vs US$0.71 in 2Q 2022)Second quarter 2023 results: EPS: US$0.24 (down from US$0.71 in 2Q 2022). Revenue: US$58.7m (up 64% from 2Q 2022). Net income: US$1.31m (down 65% from 2Q 2022). Profit margin: 2.2% (down from 10% in 2Q 2022). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany.お知らせ • Oct 04Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2022Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2022, to shareholders of record at the close of business on November 30, 2022.Upcoming Dividend • Aug 23Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 30 August 2022. Payment date: 15 September 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.2%).Recent Insider Transactions • Aug 20Independent Director recently sold €196k worth of stockOn the 18th of August, Evan Guillemin sold around 1k shares on-market at roughly €193 per share. In the last 3 months, there was an even bigger sale from another insider worth €313k. Insiders have been net sellers, collectively disposing of €924k more than they bought in the last 12 months.Recent Insider Transactions • Aug 10Independent Director recently bought €98k worth of stockOn the 9th of August, R. Tripeny bought around 500 shares on-market at roughly €196 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €728k more in shares than they bought in the last 12 months.Reported Earnings • Aug 05First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.39 profit in 1Q 2022)First quarter 2023 results: US$0.27 loss per share (down from US$0.39 profit in 1Q 2022). Revenue: US$50.5m (up 45% from 1Q 2022). Net loss: US$1.44m (down 172% from profit in 1Q 2022). Over the next year, revenue is forecast to grow 16%, compared to a 7.2% growth forecast for the industry in Germany.お知らせ • Jul 15Mesa Laboratories, Inc., Annual General Meeting, Jul 26, 2022Mesa Laboratories, Inc., Annual General Meeting, Jul 26, 2022, at 09:00 Mountain Standard Time. Location: corporate headquarters at 12100 West Sixth Avenue, Lakewood Colorado United States Agenda: To elect the seven director nominees named in the accompanying Proxy Statement; to approve, on a non-binding advisory basis, the compensation of named executive officers; to ratify the appointment of Plante & Moran, PLLC as independent registered public accounting firm for the year ending March 31, 2023; to hold a non-binding, advisory vote regarding the frequency of voting on the compensation paid to the Company's named executive officers; and to transact such other business as may properly come before the meeting or any postponements or adjournments thereof.お知らせ • Jul 07Mesa Labs Declares Quarterly Dividend, Payable on September 15, 2022Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2022, to shareholders of record at the close of business on August 31, 2022.お知らせ • Jun 28Mesa Laboratories, Inc. Appoints Tony Tripeny to Its Board of DirectorsMesa Laboratories, Inc. announced the appointment of Tony Tripeny to its Board of Directors (the "Board"), effective June 23, 2022. Tony was previously the Executive Vice President and Chief Financial Officer of Corning, Incorporated and retired on May 2, 2022. With Mr. Tripeny's appointment, the Mesa Laboratories, Inc. Board of Directors will be comprised of eight directors, six of whom are independent. Mr. Tripeny is likely to be appointed to the Audit Committee and brings extensive financial experience to the Board. The Board is committed to ongoing director refreshment and continues to consider new, qualified independent directors. During his 36-year career with Corning, Incorporated, Tony Tripeny held various, progressive leadership roles in the areas of corporate accounting and finance, including Executive Vice President, Chief Financial Officer and Senior Vice President, Corporate Controller and Principal Accounting Officer. He has significant operational, strategy, and M&A experience, extensive knowledge of the manufacturing, technology, and life sciences industries, and a background in international corporate accounting. Mr. Tripeny has a leadership style characterized by his ability to be steady, adaptable, and action-oriented during times of volatility and possesses a proven track record of recruiting and mentoring diverse talent. He received a bachelor's degree in economics from the University of Pennsylvania'sWharton School of Business and is a member of the Financial Executives Institute and the Institute of Management Accounting.Recent Insider Transactions • Jun 23CEO, President & Director recently sold €313k worth of stockOn the 21st of June, Gary Owens sold around 2k shares on-market at roughly €178 per share. This was the largest sale by an insider in the last 3 months. This was Gary's only on-market trade for the last 12 months.Reported Earnings • Jun 01Full year 2022 earnings releasedFull year 2022 results: Revenue: US$184.3m (up 38% from FY 2021). Net income: US$1.87m (down 43% from FY 2021). Profit margin: 1.0% (down from 2.4% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 24%, compared to a 7.1% growth forecast for the industry in Germany.Upcoming Dividend • May 20Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 27 May 2022. Payment date: 15 June 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.4%). Lower than average of industry peers (1.2%).お知らせ • Apr 12Mesa Laboratories, Inc. Announces Termination of Greg DiNoia as Senior Vice President of Commercial Operations, Effective June 30, 2022Mesa Laboratories, Inc. and Mr. Greg DiNoia, Senior Vice President of Commercial Operations, have agreed that Mr. DiNoia’s employment will be terminated and he will leave the company on June 30, 2022 pursuant to Section 5(d) of his Executive Employment Agreement dated September 29, 2021, which was filed on that date on Form 8-K.お知らせ • Apr 07Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2022Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2022, to shareholders of record at the close of business on May 31, 2022.Upcoming Dividend • Feb 18Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 25 February 2022. Payment date: 15 March 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (1.1%).Reported Earnings • Feb 04Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: US$0.39 loss per share (up from US$0.89 loss in 3Q 2021). Revenue: US$54.7m (up 60% from 3Q 2021). Net loss: US$2.06m (loss narrowed 55% from 3Q 2021). Revenue exceeded analyst estimates by 23%. Over the next year, revenue is forecast to grow 18%, compared to a 14% growth forecast for the industry in Germany.Upcoming Dividend • Nov 22Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 29 November 2021. Payment date: 15 December 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.8%).Recent Insider Transactions • Nov 10Insider recently sold €78k worth of stockOn the 8th of November, Gregory DiNoia sold around 280 shares on-market at roughly €279 per share. In the last 3 months, there was an even bigger sale from another insider worth €137k. Insiders have been net sellers, collectively disposing of €3.7m more than they bought in the last 12 months.Reported Earnings • Nov 05Second quarter 2022 earnings released: EPS US$0.71 (vs US$0.52 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: US$35.8m (up 13% from 2Q 2021). Net income: US$3.72m (up 39% from 2Q 2021). Profit margin: 10% (up from 8.4% in 2Q 2021). The increase in margin was driven by higher revenue.お知らせ • Sep 15Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. from its shareholders for approximately $300 million.Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. from its shareholders for approximately $300 million on September 13, 2021. Mesa will acquire 11.4 million common shares and 33.4 million preferred stock. Mesa expects to finance the all-cash transaction with a combination of cash on hand and proceeds from our credit facility. Peter Dansky, Chief Executive Officer of Agena, will join Mesa to lead the new Clinical Genomics Division. The transaction is subject to customary conditions, including receipt of applicable regulatory approvals and Mesa Laboratories shareholder approval. The transaction is approved by the boards of Mesa and Agena. The transaction is expected to be completed in Mesa’s third fiscal quarter ending December 31, 2021. Transaction is accretive to Mesa on multiple levels. Jefferies LLC acted as a financial adviser and Mike Brown and David Clark of DLA Piper LLP (US) acted as a legal adviser to Agena Bioscience. Davis Graham & Stubbs LLP acted as a legal adviser to Mesa Laboratories.Recent Insider Transactions • Sep 03Independent Director recently sold €137k worth of stockOn the 31st of August, David Kelly sold around 603 shares on-market at roughly €226 per share. In the last 3 months, there was an even bigger sale from another insider worth €1.4m. Insiders have been net sellers, collectively disposing of €3.7m more than they bought in the last 12 months.Upcoming Dividend • Aug 23Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 30 August 2021. Payment date: 15 September 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (0.8%).Recent Insider Transactions • Aug 13Insider recently sold €152k worth of stockOn the 9th of August, Brian Archbold sold around 639 shares on-market at roughly €238 per share. In the last 3 months, there was an even bigger sale from another insider worth €1.4m. Insiders have been net sellers, collectively disposing of €3.6m more than they bought in the last 12 months.お知らせ • Jun 28Mesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell Small Cap Comp Growth IndexMesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell Small Cap Comp Growth Index収支内訳Mesa Laboratories の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史DB:MLI 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費31 Mar 2624971192031 Dec 2524841172030 Sep 25245-21172030 Jun 25242-11172031 Mar 25241-21152031 Dec 24238-2491112030 Sep 24228-2461121930 Jun 24224-2501111931 Mar 24216-2541111931 Dec 2321311111930 Sep 23214-11062030 Jun 2321921072031 Mar 2321911102031 Dec 22222-11122130 Sep 22223-41142130 Jun 22200-21031931 Mar 221842891631 Dec 211638761330 Sep 211435681130 Jun 211394661131 Mar 211343641031 Dec 20130-2601030 Sep 20128-258930 Jun 20121-254831 Mar 20118251631 Dec 19110546530 Sep 191051040430 Jun 19104840431 Mar 19103740431 Dec 181041037330 Sep 18101-236330 Jun 1899035331 Mar 1896-335431 Dec 1794-434430 Sep 17941134430 Jun 17951134431 Mar 17941133431 Dec 16941233430 Sep 16901133430 Jun 16881031431 Mar 16851129431 Dec 1578928430 Sep 15769274質の高い収益: MLIは 高品質の収益 を持っています。利益率の向上: MLI過去に利益を上げました。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MLI過去 5 年間で収益を上げており、収益は年間-37.2%増加しています。成長の加速: MLIは昨年収益を上げたため、収益成長率を 5 年間の平均と比較することは困難です。収益対業界: MLI昨年収益を上げたため、昨年の収益成長をLife Sciences業界 ( 8.5% ) と比較することは困難です。株主資本利益率高いROE: MLIの 自己資本利益率 ( 3.6% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/01 15:39終値2026/07/01 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Mesa Laboratories, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。7 アナリスト機関Paul KnightBrean Capital Historical (Janney Montgomery)Vijay KumarEvercore ISITycho PetersonJefferies LLC4 その他のアナリストを表示
Reported Earnings • May 27Full year 2026 earnings released: EPS: US$1.22 (vs US$0.36 loss in FY 2025)Full year 2026 results: EPS: US$1.22 (up from US$0.36 loss in FY 2025). Revenue: US$249.1m (up 3.4% from FY 2025). Net income: US$6.71m (up US$8.69m from FY 2025). Profit margin: 2.7% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • May 06Mesa Laboratories, Inc. to Report Q4, 2026 Results on May 27, 2026Mesa Laboratories, Inc. announced that they will report Q4, 2026 results at 6:00 AM, US Eastern Standard Time on May 27, 2026
お知らせ • Oct 03+ 1 more updateMesa Laboratories, Inc. to Report Q2, 2026 Results on Nov 06, 2025Mesa Laboratories, Inc. announced that they will report Q2, 2026 results After-Market on Nov 06, 2025
お知らせ • Jul 03Mesa Laboratories, Inc. to Report Q1, 2026 Results on Aug 05, 2025Mesa Laboratories, Inc. announced that they will report Q1, 2026 results at 8:00 AM, US Eastern Standard Time on Aug 05, 2025
お知らせ • Jan 19Mesa Laboratories, Inc. to Report Q3, 2025 Results on Feb 04, 2025Mesa Laboratories, Inc. announced that they will report Q3, 2025 results at 8:00 AM, Eastern Standard Time on Feb 04, 2025
Reported Earnings • Nov 08Second quarter 2025 earnings released: EPS: US$0.63 (vs US$0.23 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.63 (up from US$0.23 loss in 2Q 2024). Revenue: US$57.8m (up 8.8% from 2Q 2024). Net income: US$3.43m (up US$4.66m from 2Q 2024). Profit margin: 5.9% (up from net loss in 2Q 2024). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions • Jun 29Insider recently sold €197k worth of stockOn the 22nd of June, Brian Archbold sold around 3k shares on-market at roughly €78.21 per share. This transaction amounted to 28% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €197k more than they bought in the last 12 months.
お知らせ • Jun 16Mesa Laboratories, Inc. Announces Appointment of Lyndsey Crennen as Chief Accounting OfficerMesa Laboratories, Inc. approved the appointment of Lyndsey Crennen as the Chief Accounting Officer of the Company, effective as of her entry into the Employment Agreement. Lyndsey Crennen, age 41, has over 20 years of experience in accounting and related roles. Lyndsey Crennen joined Mesa in 2018 as Assistant Controller and has held progressive accounting roles at the Company, including serving as Corporate Controller since 2022. Prior to joining Mesa, Lyndsey Crennen worked at Chipotle Mexican Grill, Inc., where she led the internal audit function from 2012 to 2014 and subsequently oversaw technical accounting and financial reporting through 2018. Lyndsey Crennen began her career as an auditor at PricewaterhouseCoopers, LLP in Denver. Lyndsey Crennen holds a B.S. degree in accounting and finance from the University of Colorado and is a Certified Public Accountant.
New Risk • Jun 04New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.7x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (1.7x net interest cover). Minor Risk Share price has been volatile over the past 3 months (9.5% average weekly change).
New Risk • May 28New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • May 27Full year 2026 earnings released: EPS: US$1.22 (vs US$0.36 loss in FY 2025)Full year 2026 results: EPS: US$1.22 (up from US$0.36 loss in FY 2025). Revenue: US$249.1m (up 3.4% from FY 2025). Net income: US$6.71m (up US$8.69m from FY 2025). Profit margin: 2.7% (up from net loss in FY 2025). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Declared Dividend • May 20Third quarter dividend of US$0.16 announcedShareholders will receive a dividend of US$0.16. Ex-date: 29th May 2026 Payment date: 15th June 2026 Dividend yield will be 0.7%, which is higher than the industry average of 0.5%. Payout Ratios Payout ratio: 94%. Cash payout ratio: 9%.
お知らせ • May 06Mesa Laboratories, Inc. to Report Q4, 2026 Results on May 27, 2026Mesa Laboratories, Inc. announced that they will report Q4, 2026 results at 6:00 AM, US Eastern Standard Time on May 27, 2026
お知らせ • Apr 03Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2026Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2026, to shareholders of record at the close of business on May 29, 2026.
お知らせ • Mar 10+ 1 more updateMesa Laboratories, Inc. Announces Management Changes, Effective on or About April 13, 2026On March 3, 2026, Mesa Laboratories, Inc. initiated a leadership transition pursuant to which Gary Owens will depart as President of the Company, effective on or about April 13, 2026 (the “Transition Date”). In connection with Mr. Owens’ departure, the Board has appointed Dr. Siddhartha Kadia to serve as the Company’s new President and Chief Executive Officer, effective on or about April 13, 2026 (the “Effective Date”). The Board has also approved the appointment of Dr. Kadia as a member of the Board, effective as of the Effective Date. Dr. Kadia, age 56, is an experienced executive with over 20 years in the life sciences, diagnostics and biotechnology sectors. Since January 2025, Dr. Kadia has served as Chief Executive Officer of Calibre Scientific, a diversified global provider of life science reagents, tools, instruments, and other consumables to the lab research, diagnostics and biopharmaceutical communities. From March 2022 to August 2023, he served as Chief Executive Officer of PhenomeX and its predecessor Berkeley Lights until its acquisition by Bruker Corporation. From 2014 to 2018, he served as Chief Executive Officer of EAG Laboratories. From 2005 to 2014, he served in various roles at Life Technologies (formerly Invitrogen Corporation), including President of the company’s Life Sciences Division, until the company was acquired by Thermo Fisher Scientific. Dr. Kadia began his career at consultancy firm McKinsey & Company, where he worked from 2001 to 2005. Dr. Kadia holds a Ph.D. in Biomedical Engineering from Johns Hopkins University School of Medicine, where he was honored with the David Israel Macht Award for Excellence in Research, and a Masters of Science in Biomedical Engineering from Rutgers University.
お知らせ • Feb 18Mesa Laboratories, Inc. Announces Renewed Commitment to Advancing Primary Standard Calibration Technology Through its DryCal Product LineMesa Laboratories, Inc. announced a renewed commitment to advancing primary standard calibration technology through its DryCal product line, as occupational health and safety professionals confront rising regulatory scrutiny and a generational workforce transition that threatens the integrity of workplace exposure monitoring. Across industries from pharmaceutical manufacturing to construction, worker safety depends on the accuracy of air sampling pumps used to measure exposure to hazardous substances. Those pumps must be calibrated to strict standards set by the Occupational Safety and Health Administration (OSHA) and the National Institute for Occupational Safety and Health (NIOSH), which require calibrator accuracy of +-1%. Yet a growing share of the calibration market relies on secondary standard instruments that can degrade to +-4-20% error at low flow rates, the very conditions most critical to detecting harmful exposures. Mesa's DryCal technology uses a proprietary piston prover, a primary standard that measures gas flow directly from fundamental SI quantities of volume and time. Unlike secondary standards, which derive flow measurements directly from pressure drop, temperature, and gas viscosity assumptions, a primary standard maintains accuracy across its full operating range without depending on environmental conditions or gas-specific properties. If contamination enters the measurement cell, the DryCal's piston stops moving before it can produce an inaccurate reading, a fail-safe design that secondary instruments, which can drift silently when compromised, do not offer. The distinction between primary and secondary standards has taken on new urgency as OSHA has chosen to standardize its own field enforcement operations on Mesa's Defender series calibrators, purchasing more than 120 units in 2025 with additional orders planned for 2026. As part of its commitment to advancing calibration education across the profession, Mesa Labs is partnering with the American Industrial Hygiene Association (AIHA) to present a webinar, "Flow Calibration Essentials for the OHS Professional," featuring Parameshwar alongside Laurence R. Durio, M.S., CIH, a certified industrial hygienist with more than 50 years of experience, including prior service with OSHA enforcement. The session addresses the science behind primary standards, regulatory requirements, and best practices for avoiding sample inspections. A recording is available through the AIHA website. Mesa's Calibration Solutions division continues to invest in education, product innovation, and expanded service capabilities to support occupational health and safety professionals worldwide. The company's mission, Protecting the V vulnerable®?, is reflected in its commitment to ensuring that the instruments behind workplace exposure decisions meet the highest standards of accuracy and defensibility.
お知らせ • Jan 08Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 16, 2026Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 16, 2026, to shareholders of record at the close of business on February 28, 2026.
お知らせ • Nov 07Mesa Laboratories, Inc. Provides Revenue Guidance for the Third Quarter 2026Mesa Laboratories, Inc. provided revenue guidance for the third quarter 2026. For the quarter, the company expect revenues to sequentially increase.
お知らせ • Oct 03+ 1 more updateMesa Laboratories, Inc. to Report Q2, 2026 Results on Nov 06, 2025Mesa Laboratories, Inc. announced that they will report Q2, 2026 results After-Market on Nov 06, 2025
お知らせ • Jul 14Mesa Laboratories, Inc., Annual General Meeting, Aug 22, 2025Mesa Laboratories, Inc., Annual General Meeting, Aug 22, 2025. Location: mesa laboratories, lakewood, colorado 80228, United States
お知らせ • Jul 04Mesa Labs Declares Quarterly Dividend, Payable on September 15, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025.
お知らせ • Jul 03Mesa Laboratories, Inc. to Report Q1, 2026 Results on Aug 05, 2025Mesa Laboratories, Inc. announced that they will report Q1, 2026 results at 8:00 AM, US Eastern Standard Time on Aug 05, 2025
お知らせ • Jun 30+ 7 more updatesMesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell 2000 Value IndexMesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell 2000 Value Index
お知らせ • Apr 08Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 16, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 16, 2025, to shareholders of record at the close of business on May 30, 2025.
お知らせ • Jan 19Mesa Laboratories, Inc. to Report Q3, 2025 Results on Feb 04, 2025Mesa Laboratories, Inc. announced that they will report Q3, 2025 results at 8:00 AM, Eastern Standard Time on Feb 04, 2025
お知らせ • Jan 07Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 17, 2025Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 17, 2025, to shareholders of record at the close of business on February 28, 2025.
Reported Earnings • Nov 08Second quarter 2025 earnings released: EPS: US$0.63 (vs US$0.23 loss in 2Q 2024)Second quarter 2025 results: EPS: US$0.63 (up from US$0.23 loss in 2Q 2024). Revenue: US$57.8m (up 8.8% from 2Q 2024). Net income: US$3.43m (up US$4.66m from 2Q 2024). Profit margin: 5.9% (up from net loss in 2Q 2024). Revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 113 percentage points per year, which is a significant difference in performance.
Recent Insider Transactions • Nov 01CEO, President & Director recently sold €529k worth of stockOn the 29th of October, Gary Owens sold around 5k shares on-market at roughly €104 per share. This transaction amounted to 10% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Gary's only on-market trade for the last 12 months.
Declared Dividend • Oct 06First quarter dividend of US$0.16 announcedShareholders will receive a dividend of US$0.16. Ex-date: 29th November 2024 Payment date: 16th December 2024 Dividend yield will be 0.5%, which is about the same as the industry average.
お知らせ • Oct 03Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 16, 2024Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 16, 2024, to shareholders of record at the close of business on November 29, 2024.
Declared Dividend • Jul 29Fourth quarter dividend of US$0.16 announcedShareholders will receive a dividend of US$0.16. Ex-date: 30th August 2024 Payment date: 16th September 2024 Dividend yield will be 0.6%, which is about the same as the industry average.
お知らせ • Jul 22Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024Mesa Laboratories, Inc., Annual General Meeting, Aug 30, 2024. Location: corporate headquarters at 12100 west sixth avenue, lakewood, colorado 80228., United States
お知らせ • Jul 09Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on September 16, 2024Mesa Laboratories, Inc. announced that its Board of Directors have declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 16, 2024, to shareholders of record at the close of business on August 30, 2024.
お知らせ • Jun 16Mesa Laboratories, Inc. announced delayed annual 10-K filingOn 06/14/2024, Mesa Laboratories, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
Reported Earnings • Jun 06Full year 2024 earnings released: US$47.21 loss per share (vs US$0.17 profit in FY 2023)Full year 2024 results: US$47.21 loss per share (down from US$0.17 profit in FY 2023). Revenue: US$216.2m (down 1.3% from FY 2023). Net loss: US$254.2m (down US$255.2m from profit in FY 2023). Revenue is forecast to grow 7.4% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 133 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 06Mesa Laboratories, Inc. Reports Impairment of Goodwill and Long-Lived Assets for the Fourth Quarter Ended March 31, 2024Mesa Laboratories, Inc. reported Impairment of goodwill and long-lived assets for the fourth quarter ended March 31, 2024 of $274,533,000.
New Risk • May 31New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.3x net interest cover). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Large one-off items impacting financial results.
Upcoming Dividend • May 24Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 31 May 2024. Payment date: 14 June 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (4.6%). In line with average of industry peers (0.6%).
Declared Dividend • Apr 15Third quarter dividend of US$0.16 announcedShareholders will receive a dividend of US$0.16. Ex-date: 31st May 2024 Payment date: 14th June 2024 Dividend yield will be 0.6%, which is higher than the industry average of 0.5%. Payout Ratios Payout ratio: 363%. Cash payout ratio: 8%.
お知らせ • Apr 05Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on June 14, 2024Mesa Laboratories, Inc. announced that its board of directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 14, 2024, to shareholders of record at the close of business on May 31, 2024.
New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.3x net interest cover). Minor Risks Share price has been volatile over the past 3 months (7.5% average weekly change). Large one-off items impacting financial results.
お知らせ • Apr 02Mesa Laboratories, Inc. to Report Q4, 2024 Results on May 24, 2024Mesa Laboratories, Inc. announced that they will report Q4, 2024 results at 8:00 AM, US Eastern Standard Time on May 24, 2024
Upcoming Dividend • Feb 21Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 28 February 2024. Payment date: 15 March 2024. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.6%. Lower than top quartile of German dividend payers (5.2%). In line with average of industry peers (0.7%).
Reported Earnings • Feb 05Third quarter 2024 earnings released: EPS: US$0.39 (vs US$0.084 in 3Q 2023)Third quarter 2024 results: EPS: US$0.39 (up from US$0.084 in 3Q 2023). Revenue: US$53.5m (down 1.5% from 3Q 2023). Net income: US$2.12m (up 369% from 3Q 2023). Profit margin: 4.0% (up from 0.8% in 3Q 2023). The increase in margin was driven by lower expenses. Revenue is forecast to grow 9.2% p.a. on average during the next 3 years, compared to a 10.0% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has only fallen by 29% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 08Mesa Laboratories, Inc. Appoints Mark Capone to Its Board of DirectorsMesa Laboratories, Inc. announced the appointment of Mark Capone to its Board of Directors, effective January 5, 2024. Following Mr. Capone’s election, the Mesa Board will be comprised of 7 directors, the majority of whom are independent. The Board is committed to ongoing director refreshment and continues to consider new, qualified independent directors. Mr. Capone most recently served as CEO and President of Myriad Genetics for five years. Prior to his appointment as CEO and President, he held various progressive leadership roles at Myriad Genetics, with a total tenure of 17 years at the company. During his leadership tenure, he oversaw Myriad Genetics’ growth from an early-stage pioneer in molecular diagnostics into a leading global precision medicine company. Prior to his tenure at Myriad Genetics, Mr. Capone spent 17 years with Eli Lilly and Company in positions across the entire value chain. In addition to his executive leadership positions, Mr. Capone is a Non-Executive Director and member of the Compensation Committee for of Owlstone Medical Ltd, a breath biopsy diagnostic company focused on early detection of cancer and precision medicine, and a Non-Executive Director and member of the Audit Committee and Financing Committee of DermTech, a U.S. based company focused on early melanoma detection and other skin applications. Previously, Mr. Capone was a director at Abcam PLC, helping to guide that company through its acquisition by Danaher Corporation. Mr. Capone holds a Bachelor of Science in Chemical Engineering from Pennsylvania State University and a M.Sc. in Management and a M.Sc.in Chemical Engineering from Massachusetts Institute of Technology.
お知らせ • Jan 05Mesa Laboratories, Inc. Declares Regular Quarterly Dividend, Payable on March 15, 2024Mesa Laboratories, Inc. announced that on January 2, 2024 its Board of Directors declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2024, to shareholders of record at the close of business on February 29, 2024.
お知らせ • Dec 15Mesa Laboratories, Inc. to Report Q3, 2024 Results on Feb 05, 2024Mesa Laboratories, Inc. announced that they will report Q3, 2024 results at 8:00 AM, US Eastern Standard Time on Feb 05, 2024
Upcoming Dividend • Nov 22Upcoming dividend of US$0.16 per share at 0.7% yieldEligible shareholders must have bought the stock before 29 November 2023. Payment date: 15 December 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.7%. Lower than top quartile of German dividend payers (5.0%). Lower than average of industry peers (0.9%).
New Risk • Nov 15New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
Reported Earnings • Nov 07Second quarter 2024 earnings released: US$0.23 loss per share (vs US$0.24 profit in 2Q 2023)Second quarter 2024 results: US$0.23 loss per share (down from US$0.24 profit in 2Q 2023). Revenue: US$53.2m (down 9.5% from 2Q 2023). Net loss: US$1.23m (down 194% from profit in 2Q 2023). Revenue is forecast to grow 8.6% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has fallen by 27% per year, which means it is performing significantly worse than earnings.
お知らせ • Oct 18Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million.Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Beijing GKE Science & Technology Co. LTD for €5 million on October 16, 2023. The total purchase price for the acquisition of the entity along with other 2 entities is €85 million, subject to customary purchase price adjustments and holdbacks. Collectively the three entities are referred to as “GKE”. The transactions were or will be funded with proceeds from our credit facility and cash on hand. The transaction is subject to customary conditions, including receipt of applicable Chinese regulatory approvals and is expected to be completed during our third quarter ending December 31, 2023.
お知らせ • Oct 17Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million.Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH for €80 million on October 16, 2023. The consideration will be paid in cash and will be funded with proceeds from credit facility and cash on hand. In a related transaction Mesa Laboratories, Inc. (NasdaqGS:MLAB) will acquire Beijing GKE Science & Technology Co. LTD for €5 million. Mesa Laboratories, Inc. (NasdaqGS:MLAB) completed the acquisition of Sterilization indicators business of GKE-GmbH and SAL GmbH from Gke-GmbH on October 16, 2023.
お知らせ • Oct 05Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2023Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2023, to shareholders of record at the close of business on November 30, 2023.
お知らせ • Sep 14Mesa Laboratories, Inc. to Report Q2, 2024 Results on Nov 06, 2023Mesa Laboratories, Inc. announced that they will report Q2, 2024 results at 8:00 AM, US Eastern Standard Time on Nov 06, 2023
Upcoming Dividend • Aug 23Upcoming dividend of US$0.16 per share at 0.5% yieldEligible shareholders must have bought the stock before 30 August 2023. Payment date: 15 September 2023. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.5%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (0.8%).
Reported Earnings • Aug 06First quarter 2024 earnings released: US$0.10 loss per share (vs US$0.27 loss in 1Q 2023)First quarter 2024 results: US$0.10 loss per share (improved from US$0.27 loss in 1Q 2023). Revenue: US$50.6m (flat on 1Q 2023). Net loss: US$549.0k (loss narrowed 62% from 1Q 2023). Revenue is forecast to grow 5.7% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
New Risk • Jul 20New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.2% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Profit margins are more than 30% lower than last year (0.4% net profit margin). Shareholders have been diluted in the past year (2.2% increase in shares outstanding).
お知らせ • Jul 15Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023Mesa Laboratories, Inc., Annual General Meeting, Aug 25, 2023, at 09:00 Mountain Standard Time. Location: corporate headquarters at 12100 West Sixth Avenue Lakewood Colorado United States Agenda: To consider election of six director nominees for a term of one year; to consider ratification of the selection by the company's Audit Committee of Plante & Moran, PLLC to serve as the company's independent registered public accounting firm for the fiscal year ending March 31, 2024; to consider an advisory vote on executive compensation; to consider approval of an Amendment to the 2021 Equity Incentive Plan; and to consider other matters.
お知らせ • Jun 22Mesa Laboratories, Inc. to Report Q1, 2024 Results on Aug 03, 2023Mesa Laboratories, Inc. announced that they will report Q1, 2024 results at 8:00 AM, US Eastern Standard Time on Aug 03, 2023
Reported Earnings • May 26Full year 2023 earnings released: EPS: US$0.17 (vs US$0.36 in FY 2022)Full year 2023 results: EPS: US$0.17 (down from US$0.36 in FY 2022). Revenue: US$219.1m (up 19% from FY 2022). Net income: US$930.0k (down 50% from FY 2022). Profit margin: 0.4% (down from 1.0% in FY 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.4% p.a. on average during the next 2 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Buying Opportunity • May 25Now 24% undervalued after recent price dropOver the last 90 days, the stock is down 18%. The fair value is estimated to be €174, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company became loss making.
Upcoming Dividend • May 23Upcoming dividend of US$0.16 per share at 0.4% yieldEligible shareholders must have bought the stock before 30 May 2023. Payment date: 15 June 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.7%). Lower than average of industry peers (1.7%).
お知らせ • May 10Mesa Laboratories, Inc. Announces John B. Schmieder, Member of the Board of Directors, Chair of the Nominating and Governance Committee, and Member of the Audit Committee Decide Not to Stand for Re-ElectionMesa Laboratories, Inc. announced that on May 3, 2023, John B. Schmieder, member of the Board of Directors, current Chair of the Nominating and Governance Committee, and member of the Audit Committee, informed the Board of Mesa Laboratories, Inc. that he has decided not to stand for re-election at the 2023 annual meeting of shareholders. Mr. Schmieder’s decision not to stand for re-election is not related to any disagreement with Mesa or with Mesa’s operations, policies or practices, and Mr. Schmieder will continue to serve as a director through the date of the annual meeting.
Upcoming Dividend • Feb 20Upcoming dividend of US$0.16 per share at 0.4% yieldEligible shareholders must have bought the stock before 27 February 2023. Payment date: 15 March 2023. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.4%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.7%).
Reported Earnings • Feb 08Third quarter 2023 earnings released: EPS: US$0.084 (vs US$0.39 loss in 3Q 2022)Third quarter 2023 results: EPS: US$0.084 (up from US$0.39 loss in 3Q 2022). Revenue: US$54.3m (flat on 3Q 2022). Net income: US$451.0k (up US$2.51m from 3Q 2022). Profit margin: 0.8% (up from net loss in 3Q 2022). Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Jan 04Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on March 15, 2023Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on March 15, 2023, to shareholders of record at the close of business on February 28, 2023.
お知らせ • Dec 17Mesa Laboratories, Inc. to Report Q3, 2023 Results on Feb 06, 2023Mesa Laboratories, Inc. announced that they will report Q3, 2023 results at 8:00 AM, Eastern Standard Time on Feb 06, 2023
Buying Opportunity • Dec 01Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 10%. The fair value is estimated to be €199, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Meanwhile, the company became loss making.
Upcoming Dividend • Nov 22Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 29 November 2022. Payment date: 15 December 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.9%). Lower than average of industry peers (1.5%).
お知らせ • Nov 18Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH.Mesa Laboratories, Inc. (NasdaqGS:MLAB) acquired Substantially all of the assets and certain liabilities from Belyntic GmbH on November 17, 2022. Mesa Laboratories, Inc. (NasdaqGS:MLAB) completed the acquisition of Substantially all of the assets and certain liabilities from Belyntic GmbH on November 17, 2022.
お知らせ • Nov 05+ 1 more updateMesa Laboratories, Inc. Appoints Tony Tripeny as Member of Audit CommitteeMesa Laboratories, Inc. announced on November 2, 2022, effective immediately, the Board appointed Mr. Tony Tripeny to its Audit Committee, having previously determined that he satisfies all applicable requirements to serve on the Committee, including without limitation applicable requirements of the Nasdaq Stock Market and the Securities Exchange Act of 1934, as amended.
Reported Earnings • Nov 04Second quarter 2023 earnings released: EPS: US$0.24 (vs US$0.71 in 2Q 2022)Second quarter 2023 results: EPS: US$0.24 (down from US$0.71 in 2Q 2022). Revenue: US$58.7m (up 64% from 2Q 2022). Net income: US$1.31m (down 65% from 2Q 2022). Profit margin: 2.2% (down from 10% in 2Q 2022). Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Germany.
お知らせ • Oct 04Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on December 15, 2022Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on December 15, 2022, to shareholders of record at the close of business on November 30, 2022.
Upcoming Dividend • Aug 23Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 30 August 2022. Payment date: 15 September 2022. The company is not currently making a profit but it is cash flow positive. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.6%). Lower than average of industry peers (1.2%).
Recent Insider Transactions • Aug 20Independent Director recently sold €196k worth of stockOn the 18th of August, Evan Guillemin sold around 1k shares on-market at roughly €193 per share. In the last 3 months, there was an even bigger sale from another insider worth €313k. Insiders have been net sellers, collectively disposing of €924k more than they bought in the last 12 months.
Recent Insider Transactions • Aug 10Independent Director recently bought €98k worth of stockOn the 9th of August, R. Tripeny bought around 500 shares on-market at roughly €196 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold €728k more in shares than they bought in the last 12 months.
Reported Earnings • Aug 05First quarter 2023 earnings released: US$0.27 loss per share (vs US$0.39 profit in 1Q 2022)First quarter 2023 results: US$0.27 loss per share (down from US$0.39 profit in 1Q 2022). Revenue: US$50.5m (up 45% from 1Q 2022). Net loss: US$1.44m (down 172% from profit in 1Q 2022). Over the next year, revenue is forecast to grow 16%, compared to a 7.2% growth forecast for the industry in Germany.
お知らせ • Jul 15Mesa Laboratories, Inc., Annual General Meeting, Jul 26, 2022Mesa Laboratories, Inc., Annual General Meeting, Jul 26, 2022, at 09:00 Mountain Standard Time. Location: corporate headquarters at 12100 West Sixth Avenue, Lakewood Colorado United States Agenda: To elect the seven director nominees named in the accompanying Proxy Statement; to approve, on a non-binding advisory basis, the compensation of named executive officers; to ratify the appointment of Plante & Moran, PLLC as independent registered public accounting firm for the year ending March 31, 2023; to hold a non-binding, advisory vote regarding the frequency of voting on the compensation paid to the Company's named executive officers; and to transact such other business as may properly come before the meeting or any postponements or adjournments thereof.
お知らせ • Jul 07Mesa Labs Declares Quarterly Dividend, Payable on September 15, 2022Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2022, to shareholders of record at the close of business on August 31, 2022.
お知らせ • Jun 28Mesa Laboratories, Inc. Appoints Tony Tripeny to Its Board of DirectorsMesa Laboratories, Inc. announced the appointment of Tony Tripeny to its Board of Directors (the "Board"), effective June 23, 2022. Tony was previously the Executive Vice President and Chief Financial Officer of Corning, Incorporated and retired on May 2, 2022. With Mr. Tripeny's appointment, the Mesa Laboratories, Inc. Board of Directors will be comprised of eight directors, six of whom are independent. Mr. Tripeny is likely to be appointed to the Audit Committee and brings extensive financial experience to the Board. The Board is committed to ongoing director refreshment and continues to consider new, qualified independent directors. During his 36-year career with Corning, Incorporated, Tony Tripeny held various, progressive leadership roles in the areas of corporate accounting and finance, including Executive Vice President, Chief Financial Officer and Senior Vice President, Corporate Controller and Principal Accounting Officer. He has significant operational, strategy, and M&A experience, extensive knowledge of the manufacturing, technology, and life sciences industries, and a background in international corporate accounting. Mr. Tripeny has a leadership style characterized by his ability to be steady, adaptable, and action-oriented during times of volatility and possesses a proven track record of recruiting and mentoring diverse talent. He received a bachelor's degree in economics from the University of Pennsylvania'sWharton School of Business and is a member of the Financial Executives Institute and the Institute of Management Accounting.
Recent Insider Transactions • Jun 23CEO, President & Director recently sold €313k worth of stockOn the 21st of June, Gary Owens sold around 2k shares on-market at roughly €178 per share. This was the largest sale by an insider in the last 3 months. This was Gary's only on-market trade for the last 12 months.
Reported Earnings • Jun 01Full year 2022 earnings releasedFull year 2022 results: Revenue: US$184.3m (up 38% from FY 2021). Net income: US$1.87m (down 43% from FY 2021). Profit margin: 1.0% (down from 2.4% in FY 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 24%, compared to a 7.1% growth forecast for the industry in Germany.
Upcoming Dividend • May 20Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 27 May 2022. Payment date: 15 June 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (4.4%). Lower than average of industry peers (1.2%).
お知らせ • Apr 12Mesa Laboratories, Inc. Announces Termination of Greg DiNoia as Senior Vice President of Commercial Operations, Effective June 30, 2022Mesa Laboratories, Inc. and Mr. Greg DiNoia, Senior Vice President of Commercial Operations, have agreed that Mr. DiNoia’s employment will be terminated and he will leave the company on June 30, 2022 pursuant to Section 5(d) of his Executive Employment Agreement dated September 29, 2021, which was filed on that date on Form 8-K.
お知らせ • Apr 07Mesa Laboratories, Inc. Declares Quarterly Dividend, Payable on June 15, 2022Mesa Laboratories, Inc. announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on June 15, 2022, to shareholders of record at the close of business on May 31, 2022.
Upcoming Dividend • Feb 18Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 25 February 2022. Payment date: 15 March 2022. Payout ratio is a comfortable 44% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of German dividend payers (3.3%). Lower than average of industry peers (1.1%).
Reported Earnings • Feb 04Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beatThird quarter 2022 results: US$0.39 loss per share (up from US$0.89 loss in 3Q 2021). Revenue: US$54.7m (up 60% from 3Q 2021). Net loss: US$2.06m (loss narrowed 55% from 3Q 2021). Revenue exceeded analyst estimates by 23%. Over the next year, revenue is forecast to grow 18%, compared to a 14% growth forecast for the industry in Germany.
Upcoming Dividend • Nov 22Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 29 November 2021. Payment date: 15 December 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.2%). Lower than average of industry peers (0.8%).
Recent Insider Transactions • Nov 10Insider recently sold €78k worth of stockOn the 8th of November, Gregory DiNoia sold around 280 shares on-market at roughly €279 per share. In the last 3 months, there was an even bigger sale from another insider worth €137k. Insiders have been net sellers, collectively disposing of €3.7m more than they bought in the last 12 months.
Reported Earnings • Nov 05Second quarter 2022 earnings released: EPS US$0.71 (vs US$0.52 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: US$35.8m (up 13% from 2Q 2021). Net income: US$3.72m (up 39% from 2Q 2021). Profit margin: 10% (up from 8.4% in 2Q 2021). The increase in margin was driven by higher revenue.
お知らせ • Sep 15Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. from its shareholders for approximately $300 million.Mesa Laboratories, Inc. (NasdaqGS:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. from its shareholders for approximately $300 million on September 13, 2021. Mesa will acquire 11.4 million common shares and 33.4 million preferred stock. Mesa expects to finance the all-cash transaction with a combination of cash on hand and proceeds from our credit facility. Peter Dansky, Chief Executive Officer of Agena, will join Mesa to lead the new Clinical Genomics Division. The transaction is subject to customary conditions, including receipt of applicable regulatory approvals and Mesa Laboratories shareholder approval. The transaction is approved by the boards of Mesa and Agena. The transaction is expected to be completed in Mesa’s third fiscal quarter ending December 31, 2021. Transaction is accretive to Mesa on multiple levels. Jefferies LLC acted as a financial adviser and Mike Brown and David Clark of DLA Piper LLP (US) acted as a legal adviser to Agena Bioscience. Davis Graham & Stubbs LLP acted as a legal adviser to Mesa Laboratories.
Recent Insider Transactions • Sep 03Independent Director recently sold €137k worth of stockOn the 31st of August, David Kelly sold around 603 shares on-market at roughly €226 per share. In the last 3 months, there was an even bigger sale from another insider worth €1.4m. Insiders have been net sellers, collectively disposing of €3.7m more than they bought in the last 12 months.
Upcoming Dividend • Aug 23Upcoming dividend of US$0.16 per shareEligible shareholders must have bought the stock before 30 August 2021. Payment date: 15 September 2021. Trailing yield: 0.2%. Lower than top quartile of German dividend payers (3.1%). Lower than average of industry peers (0.8%).
Recent Insider Transactions • Aug 13Insider recently sold €152k worth of stockOn the 9th of August, Brian Archbold sold around 639 shares on-market at roughly €238 per share. In the last 3 months, there was an even bigger sale from another insider worth €1.4m. Insiders have been net sellers, collectively disposing of €3.6m more than they bought in the last 12 months.
お知らせ • Jun 28Mesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell Small Cap Comp Growth IndexMesa Laboratories, Inc.(NasdaqGS:MLAB) dropped from Russell Small Cap Comp Growth Index